This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Exonate encompasses scientific excellence in everything we do

Key Publications - Ophthalmology

Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. Batson J, Toop HD, Redondo C et al. ACS Chem Biol. 2017 

Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina. Ved N, Hulse RP, Bestall SM, Donaldson LF, Bainbridge JW, Bates DO. Clinical Science. 2017 

VEGF-A165b is cytoprotective and antiangiogenic in the retina. Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ. Invest Ophthalmol Vis Sci. 2010 

Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Hua J, Spee C, Kase S, Rennel ES, Magnussen AL, Qiu Y, Varey A, Dhayade S, Churchill AJ, Harper SJ, Bates DO, Hinton DR. Invest Ophthalmol Vis Sci. 2010 

SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Gammons MV, Dick AD, Harper SJ, Bates DO. Invest Ophthalmol Vis Sci. 2013

Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Gammons MV, Fedorov O, Ivison D, Du C, Clark T, Hopkins C, Hagiwara M, Dick AD, Cox R, Harper SJ, Hancox JC, Knapp S, Bates DO. Invest Ophthalmol Vis Sci. 2013 

Conference Abstracts- Ophthalmology

EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema, inhibits ocular neovascularisation. Batson J, Toop H, Liddell S, et al. Investigative Ophthalmology & Visual Science July 2019. 

Targeting SRPK1 with novel potent and selective small molecule inhibitors inhibits choroidal neovascularisation through modulating VEGF-A alternative splicing. Bates DO, Toop H, Daubney J, Stewart E, Morris J, Batson J. Investigative Ophthalmology & Visual Science 2017.

Novel SRPK1 inhibitors specifically target alternative splicing in human primary retinal epithelial cells. Rowlinson J, Batson J, Toop H, Allen C, Gibbons B, Babaei‐Jadidi R, Zhang J, Wearmouth S, Knapp S, Morris J, Bates D. Acta Ophthalmologica 2015. 

SRPK1 inhibitors as novel anti‐angiogenic therapeutics for wet age‐related macular degeneration (wAMD). Batson J, Toop H, Rowlinson J, Allen C, Gibbons B et al. Acta Ophthalmologica, 2015.